Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 9, 2020

Primary Completion Date

September 28, 2022

Study Completion Date

December 31, 2025

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

epirubicin hydrochloride

Take epirubicin hydrochloride (90mg/m2, d1) every 14 days as one cycle for 4 cycles with cyclophosphamide, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.

DRUG

Cyclophosphamide

Take cyclophosphamide (600mg/m2, d1) every 14 days as one cycle for 4 cycles with epirubicin hydrochloride, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.

DRUG

Albumin bound paclitaxel

Take nanoparticlealbumin-bound paclitaxel (125mg/m2, d1) per week for 3 weeks as one cycle for 4 cycles with Toripalimab, following epirubicin hydrochloride and cyclophosphamide.

DRUG

Toripalimab

Take Toripalimab (240mg, d1) every 3 weeks as one cycle for 4 cycles with nanoparticlealbumin-bound paclitaxel, following epirubicin hydrochloride and cyclophosphamide.

Trial Locations (1)

200000

Shanghai Cancer Center, Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER